+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06320431

Optimizing Intravenous Tenecteplase Use for Acute Ischemic Stroke Comparing Standard and Low Doses with No Tenecteplase in Emergency Treatment

Led by University of Calgary · Updated on 2026-10-21

4000

Participants Needed

24

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of intravenous tenecteplase for patients with acute ischemic stroke AIS. This trial aims to determine the best dose of tenecteplasestandard-dose 0.25 mgkg versus low-dose 0.18 mgkgand whether to use tenecteplase or no thrombolysis in specific patient groups, including those recently using direct oral anticoagulants DOACs and those planned for emergency endovascular thrombectomy EVT. The study addresses uncertainties in dosing and safety for various patient subgroups, such as the elderly, patients with comorbidities, and those with different brain imaging findings. Participants will be randomly assigned to receive either standard-dose or low-dose tenecteplase as a single intravenous bolus, or no tenecteplase if they are on recent DOACs or planned for EVT. The doses are administered quickly after randomization. The trial compares these approaches to find the most effective and safe use of tenecteplase for AIS treatment. The study follows participants for 90 days after treatment to assess outcomes. During the study, researchers will assess participants functional independence using the modified Rankin Scale at 90 days, along with mortality, quality of life, and imaging outcomes. Safety events like intracranial hemorrhage and serious adverse events will be monitored closely, especially within the first days after treatment. Participants will have assessments including telephone follow-ups, hospital discharge status, and brain imaging evaluations. The total participation lasts up to 90 days or until death if earlier.

CONDITIONS

Brief Title

ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Research Team

B

Bijoy K Menon, MD, MSc

C

Craig Anderson, MD, Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here